Results 191 to 200 of about 671,308 (289)

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Hepatitis D virus infection prevalence in persons with human immunodeficiency virus and hepatitis B virus coinfection in Germany. [PDF]

Infection
Elamouri F, Lutz T, Knecht G, Wyen C, Posdzich P, Monin M, Sabranski M, Hoffmann C, Killer A, Jensen BE, Malin JJ, Esser S, Mauss S, Vogelmann R, Boesecke C, Beer D, Grunwald S, Haberl A, Voit F, Qurishi N, Noe S, Khaykin P, Schneeweiß SM, Christensen S, Schwarze-Zander C, Jessen A, Boyd A, Rockstroh JK, van Bremen K.   +28 more
europepmc   +1 more source

Psychoactive prescription drug use and misuse in patients on opioid agonist treatment

British Journal of Clinical Pharmacology, EarlyView.
Aims To identify the patterns and trends in prescription drug use and misuse in patients on opioid agonist treatment. Methods We used data from the OPPIDUM programme, which collects data from patients attending substance abuse treatment facilities. Data collected include use of psychoactive prescription drugs in the past week.
Thomas Soeiro, Clémence Lacroix, Élisabeth Jouve, Élisabeth Frauger, Maryse Lapeyre‐Mestre, Joëlle Micallef   +5 more
wiley   +1 more source

Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. [PDF]

Lancet Oncol
Karagas MR, Kaldor J, Michaelis M, Muchengeti MM, Alfaiate D, Argirion I, Chen X, Cunha C, Hantz S, Koljonen V, Laude HC, Lui WO, Nevels MM, O'Brien TR, Scheurer ME, Touze A, Wiemels JL, Benbrahim-Tallaa L, de Conti A, Facchin C, Madia F, Pasqual E, Wedekind R, Aguilera-Buenosvinos I, Clifford G, Deng X, Dongoran RA, Ezzemni S, Huang Y, Suonio E, Zhai Y, Mattock H, Schubauer-Berigan MK, Kunzmann AT.   +33 more
europepmc   +1 more source

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

British Journal of Clinical Pharmacology, EarlyView.
Aims Crisugabalin is a novel calcium channel α2δ subunit ligand and a highly selective oral gamma‐aminobutyric acid (GABA) analogue developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). This study investigated pharmacokinetic properties and safety of crisugabalin in subjects with renal impairment ...
Shibeilei Lin, Ye Wang, Chao Hu, Yanhuan Feng, Xi Tang, Ping Fu, Jia Miao   +6 more
wiley   +1 more source

Multimodal characterization of the responsiveness of eight hepatitis D virus genotype isolates to interferon-alpha treatment. [PDF]

J Virol
Ding Y, Li Q, Sha Y, Si R, Feng C, Liu M, Feng Z, Ding X, Li Y, Fu H, Liang S, Yao Q, Zhang Z, Li F, Urban S, Guo H, Wang W.   +16 more
europepmc   +1 more source

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon, Sophie Delhomme, Delphine Launay, Séverine Blesson, Stéphanie Braillard, Pegah Maghdooni, Frauke Assmus, Richard Hoglund, Joel Tarning, Sabrina Loyau, Byron Arana, Mathilde Latreille‐Barbier, Yves Donazzolo   +12 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Cost-Effectiveness of One-time Universal Testing for Hepatitis D Among Adults With Chronic Hepatitis B in the United States. [PDF]

Clin Infect Dis
Toy M, Hutton D, Teshale E, Thompson WW, Pham H, Salomon JA, So S.   +6 more
europepmc   +1 more source

Long‐term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real‐world cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long‐term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30‐month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.
Nicola Perrotta, Luigi Angelo Fiorito, Roberta Vescovo, Anna Virgilio, Giulia Amato, Giuseppe Cimino   +5 more
wiley   +1 more source